Skip to main content
  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Journals
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Cancer Therapeutics
Molecular Cancer Therapeutics
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • Focus on Radiation Oncology
      • Novel Combinations
      • Reviews
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Highlights

Selected Articles from This Issue

DOI:  Published December 2020
  • Article
  • Info & Metrics
  • PDF
Loading

Emerging CAR T Cell Therapies in Triple Negative Breast Cancer

Dees et al. Page 2409

There is an unmet medical need to develop novel treatment modalities for patients with triple negative breast cancer (TNBC), an aggressive breast cancer subtyp. characterized by poor survival rates. The immunogenic nature of TNBC has prompted researchers to exploit a type of adoptive cell therapy called chimeric antigen receptor (CAR)-T cell therapy for the treatment of TNBC. Strategies to address the inherent challenges associated with CAR-T cell therapy in solid tumors and emerging targets and ongoing clinical trials for CAR-T cell therapy in TNBC are discussed in this review.

Repurposing a TPr Inhibitor to Block Cancer Metastasis

Werfel et al. Page 2454

One alternative to discovering novel drugs is to repurpose existing ones. In this study, Werfel and colleagues performed a phenome-wide association study (PheWAS) and identified clinical manifestations correlating with a thromboxane A2-prostanoid receptor (TPr) single nucleotide polymorphism associated with cancer metastasis in several cancer types. CPI211, a TPr inhibitor used in cardiovascular diseases, inhibited TPr in murine models and blocked spontaneous metastasis from primary tumors without affecting tumor proliferation. The study demonstrates the potential of drug repurposing and supports further study of CPI211.

Glutaminase Inhibitors Sensitize Resistant Cervical Cancers

Rashmi et al. Page 2465

The standard of care for the treatment of locally advanced cervical cancer includes pelvic irradiation and cisplatin chemotherapy. Patients failing chemotherap. are salvaged with surgery or cisplatin/bevacizumab, but no cures are available for metastatic or recurrent disease. Therefore, Rashmi and colleagues sought a therapy effective in radiation-resistant cervical cancer. Radiation-resistant cervical cancer cells were found to be reliant on glutamine metabolism and glutaminase inhibition with telaglenastat sensitized xenografts through thiol-mediated oxidative stress. Moreover, PI3K pathway mutations were found to predict telaglenastat sensitivity.

Immunocytokine Synergizes with Oxaliplatin in Cancer Models

Bajic et al. Page 2554

Immune checkpoint inhibitors in metastatic colorectal cancer remain only efficacious in microsatellite instable and deficient mismatch repair tumors. Alternatively, engineered cytokine products using tumor necrosis factor (TNF) can induce cell death. Bajic and colleagues outline a novel fusion of the monoclonal antibody Sm3E (targeting carcinoembryonic antigen, CEA) and TNF. The resulting fusion protein (Sm3E-TNF) was tested in immunocompetent mouse models transfected with human CEA and led to rapid necrosis of tumors that later regrew from the margin. Therefore, the authors combined Sm3E-TNF with oxaliplatin which generated complete tumor eradication in 40% of treated mice. Their results support the continued development of Sm3E-TNF for use with oxaliplatin in metastatic patients.

  • ©2020 American Association for Cancer Research.
PreviousNext
Back to top
Molecular Cancer Therapeutics: 19 (12)
December 2020
Volume 19, Issue 12
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Cancer Therapeutics article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Selected Articles from This Issue
(Your Name) has forwarded a page to you from Molecular Cancer Therapeutics
(Your Name) thought you would be interested in this article in Molecular Cancer Therapeutics.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Selected Articles from This Issue
Mol Cancer Ther December 1 2020 (19) (12) 2407;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Selected Articles from This Issue
Mol Cancer Ther December 1 2020 (19) (12) 2407;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Emerging CAR T Cell Therapies in Triple Negative Breast Cancer
    • Repurposing a TPr Inhibitor to Block Cancer Metastasis
    • Glutaminase Inhibitors Sensitize Resistant Cervical Cancers
    • Immunocytokine Synergizes with Oxaliplatin in Cancer Models
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Selected Articles from This Issue
  • Selected Articles from This Issue
  • Selected Articles from This Issue
Show more Highlights
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook  Twitter  LinkedIn  YouTube  RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Meeting Abstracts

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About MCT

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Molecular Cancer Therapeutics
eISSN: 1538-8514
ISSN: 1535-7163

Advertisement